Zhejiang Hisun

Zhejiang Hisun Pharmaceutical was founded in 1956 and issued A-shares in 2000; the company’s current profile describes it as a state-controlled listed pharmaceutical enterprise headquartered in Taizhou, Zhejiang. Hisun says it began as a chemical enterprise and entered the pharmaceutical field in the early 1970s, later building an integrated model covering drug substances and preparations [1] [2].

The company’s stated business now spans chemical drugs, biologics, animal medicines, traditional Chinese medicines and commercial distribution. Its research-and-development footprint includes centers in Taizhou, Shanghai, Hangzhou and the United States, alongside a national enterprise technology center, a provincial key laboratory and a postdoctoral research station. Hisun also records a 2012 branded-generics joint venture with Pfizer as part of its move toward a broader research, manufacturing and commercialization platform [1] [2].

The latest full-year results located in the company’s current investor materials are for 2024: an official investor-relations briefing reports revenue of RMB9.787 billion, net profit attributable to shareholders of RMB601 million and non-recurring-item-adjusted net profit of RMB423 million. Current company updates also show continuing work in international partnerships, product approvals and production-capacity upgrades, so these financial figures should be read as 2024 results rather than a 2026 run-rate [2] [3].